Preparation of extemporaneous solutions with chemotherapeutic agents for pediatric patients: Ensuring safe and effective treatment
Main Article Content
Abstract
The treatment of pediatric oncology patients involves the use of specialized drugs adapted to their specific needs, thus, in view of the need for pharmacotherapeutic follow-up with oral dosage forms (ODF), in the unavailability of liquid formulations, a strategy is the preparation of extemporaneous solutions from the manipulation of tablets and capsules added to liquid vehicles (eg: water, simple syrup) adjusting palatability and facilitating access. This review article will serve as a guide, providing information on the preparation, stability and storage of extemporaneous oral chemotherapy formulations (tablets, capsules, injection powder or injection solution) for use in clinical practice, with the aim of promoting adherence to treatment linked to safety and effectiveness, based on good handling practices and occupational risk. The results of this review are summarized in a table and based on a composition of the cited documents, tests carried out and the authors' judgment on all the data collected. Twenty drugs were identified as potentially important for clinical practice. Strategies for preparing extemporaneous solutions of chemotherapeutic agents for pediatric patients require more scientific data or even publications of adaptations used. Even with the scarcity of data for some drugs, this review covers the most trivial drugs in clinical practice, including information on preparation, warning about stability and storage, and also included relevant guidelines on the mode of administration in view of the adherence and effectiveness of the drug. The professional who handles these cytotoxic drugs needs to understand from pharmacotechnical aspects and guard against exposure in the preparation, so that he can continue to guarantee access and adherence to treatment and follow rigorous literature and protocols, implementing the best practices and providing adequate, effective, and personalized treatment.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Meleha A. E., Elsherbini E., Elsheredy A. Evaluation of Handling of Cytotoxic Drugs and Potential Occupational Risk among Health Care Workers in Pediatric Hematology/Oncology Unit. Article 160, Volume 90, Issue 2, January 2023, Page 3041-3046.
3. Resolução da diretoria colegiada- RDC nº 67, de 8 DE OUTUBRO DE 2007. Dispões sobre boas práticas de manipulação e preparações magistrais para uso humano em farmácias. Available from:< https://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2007/rdc0067_08_10_2007.html>. Access in: August 8, 2023.
4. Romero RM, Corpas MV, Medina MG, Peña CG, Romero AC, Guardia AVR de la, et al. PP-041 Extemporaneous preparation of oral liquid formulation of capecitabina. European Journal of Hospital Pharmacy. 2016 Feb 14;23(Suppl 1):A212.1-A212.
5. Allen Jr LV. Cyclophosphamide 10-mg/mL oral liquid. U.S. Pharmacist. 2010; 35. 42-43.
6. Lam MSH. Extemporaneous Compounding of Oral Liquid Dosage Formulations and Alternative Drug Delivery Methods for Anticancer Drugs. Pharmacotherapy. 2011 Feb;31(2):164–92.
7. Li Q, Liu Z, Kolli S, Wetz K, Griffith N, Poi MJ. Stability of extemporaneous erlotinib, lapatinib, and imatinib oral suspensions. Am J Health Syst Pharm. 2016;73(17):1331-1337.
doi:10.2146/ajhp150581
8. Novartis Pharmaceuticals Corporation. Afinitor (Everolimus) oral tablet product information. East Hanover, NJ; 2010.
9. Novartis Pharmaceuticals Corporation. Gleevec (imatinib mesylate) oral tablet product information. East Hanover, NJ; 2009.
10. Estepp JH, Melloni C, Thornburg CD, et al. Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia. J Clin Pharmacol. 2016;56(3):298-306. doi:10.1002/jcph.598
11. Coache D, Friciu M, Bernine Marcellin R, et al. Stability evaluation of compounded hydroxyurea 100 mg/mL oral liquids using a novel analytical method involving chemical derivatization. PLoS One. 2022;17(6):e0270206. Published 2022 Jun 24. doi:10.1371/journal.pone.0270206
12. Alwhaibi A, Alenazi M, Almadi B, Alotaibi A, Alshehri SM, Shakeel F. A practical method for oral administration of isotretinoin in pediatric oncology patient: A case study of neuroblastoma. J Oncol Pharm Pract. 2023 Apr;29(3):755-759.
13. Cohen, J., Lee J., Markham, R., Szerwo, J., Roska, M., Bubalo, J. Medication use process and assessment of extemporaneous compounding and alternative routes of administration of oral oncology drugs: Guidance for clinical and oncology pharmacists. J Am Coll Clin Pharm. 2022;5:1176–1228. doi: 10.1002/jac5.1698
14. ATTIVI, David et al. Development of microemulsion of mitotane for improvement of oral bioavailability. Drug development and industrial pharmacy, v. 36, n. 4, p. 421-427, 2010.
15. Nahata, Milap C.; and Pai, Vinita B., eds. Pediatric drug formulations. 7th ed. Cincinnati: Harvey Whitney; 2011.
16. Mercaptopurine 50 mg/ml Oral Liquid. Formulations. IJPC2006; 10(1): 64
17. Allen, L.V.J., Pazopanib 50 mg/mL Oral Suspension. US Pharm. 2015;40(10):61-62
18. Navid F, Christensen R, Inaba H, Li L, Chen Z, Cai X, Regel J, Baker SD. Alternative formulations of sorafenib for use in children. Pediatr Blood Cancer. 2013 Oct;60(10):1642-6. doi: 10.1002/pbc.24619.
19. Drug information handbook for oncology. A complete guide to combination chemoteraphy regimens. (12th ed., 2014)
20. LM Okumura, PCB Okumura, Veronesi C. Administration of all-trans retinoic acid through enteral tubes in acute promyelocytic leukemia: the handling of cytotoxic agents and clinical benefits. Rev Bras Hematol Hemoter. 2017; 39(1):86-88.
21. Gilda, SS., Kolling, WM., Nieto, M., McPherson, T. Stability and Beyond-Use Date of a Compounded Thioguanine Suspension. J Pharm Technol. 2021 Feb; 37(1): 23–29. doi: 10.1177/8755122520952436
22. Daw N, Santana V, Lacono L, et al. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors. J Clin Oncol. 2004;22(5):829–837.
23. Wagner C, Adams V, Overley C. Alternate dosage formulations of oral targeted anticancer agentes. Journal of Oncology Pharmacy Practice. 2021;27(8):1963-1981.
24. Silva, Márcio & Dysars, Letícia & Santos, Elisabete & Júnior, Eduardo. Preparation of extemporaneous oral liquid in the hospital pharmacy. Brazilian Journal of Pharmaceutical Sciences. 56. 2020.
25. Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol. 2002;42(6):620–643.
26. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan; 36 (2008). Available from:< https://go.drugbank.com/salts/DBSALT000165>. Access in: August 8, 2023.
27. NIOSH [2020]. Procedures for Developing the NIOSH List of Hazardous Drugs in Healthcare Settings. By Whittaker C, Ovesen JL, MacKenzie BA, Hartley, T, Berry KA, Piacentino J. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DH HS (NIOSH).
28. NIOSH [2023]. Managing hazardous drug exposures: information for healthcare settings. By Hodson L, Ovesen J, Couch J, Hirst D, Lawson C, Lentz TJ, MacKenzie B, Mead K. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2023-130,
https://doi.org/10.26616/NIOSHPUB2023130